EGFR and neoplasm: Two anti-EGFR LiTEs, produced in two orientations, i.e., as EGFR(Nb)/CD3(scFv) and CD3(scFv)/EGFR(Nb), showed enhanced T-cell activation and significant inhibition of EGFR-expressing tumor cells (48).